JS019
/ Shanghai Junshi Biosci, Beijing Eirene, Suzhou Kebo Ruijun Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 04, 2025
Proof-of-concept study of the CD39-blocking antibody JS019 in eosinophilic-associated disorders
(ASH 2025)
- "Eligible participants wereadults with eosinophil counts >1.5 × 10⁹/L accompanied by organ involvement, refractory or relapsedafter prior treatment, and on stable glucocorticoid therapy (prednisone ≥10 mg/day or equivalent) for ≥1month prior to screening. No Grade 4 events or dose-limiting toxicities were observed.ConclusionsThis proof-of-concept study demonstrates that CD39 blockade with JS019 induces rapid, selective andsustained eosinophil suppression in patients with eosinophilic-associated disorders, accompanied byearly clinical improvements and a favorable safety profile. These results support further clinicaldevelopment of JS019 in type 2 inflammation beyond oncology."
Atopic Dermatitis • Dermatology • Eosinophilia • Hematological Malignancies • Hypereosinophilic Syndrome • Hypotension • Immunology • ENTPD1
August 19, 2022
A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Suzhou Kebo Ruijun Biotechnology Co., Ltd
New P1 trial • Oncology • Solid Tumor • ENTPD1
May 16, 2022
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas
(clinicaltrials.gov)
- P1 | N=172 | Recruiting | Sponsor: Suzhou Kebo Ruijun Biotechnology Co., Ltd
New P1 trial • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • ENTPD1
1 to 3
Of
3
Go to page
1